Clinical Publication
RSSArticles
-
Momelotinib Tablets (Ojjaara)
Momelotinib can be prescribed to treat intermediate- or high-risk myelofibrosis.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Biomarker Profiles of Those Living to Age 100 Years
Among 1,224 participants who lived to their 100th birthday, there were higher levels of total cholesterol and iron, and lower levels of glucose, creatinine, uric acid, liver enzymes, and alkaline phosphatase compared with non-centenarians. These differences were seen as early as age 65 years.
-
Can Internet Use Prevent Dementia?
In an ongoing longitudinal survey of a nationally representative sample of dementia-free adults age 50 to 64.9 years, regular internet users experienced approximately half the risk of dementia compared with non-regular users.
-
Examining the Effect of Physical Activity and Depressive Symptoms in Adolescents
In a robust meta-analysis of 21 studies, physical activity interventions showed a significant short-term benefit for children and adolescents with depressive symptoms, particularly in those aged 13 years and older and in participants with a diagnosis of depression.
-
Canakinumab Injection (Ilaris)
Canakinumab can be prescribed to adults with gout in whom nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
-
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.
-
Treating Preclinical Alzheimer’s Disease
After studying an anti-amyloid antibody, solanezumab, researchers reported there was no benefit in reducing the likelihood of progression of cognitive impairment in patients with positive amyloid PET scans who started the trial cognitively unimpaired, compared to placebo.
-
Turmeric (Curcumin) Helps Patients with Dyspepsia and Acid Reflux
In a randomized, controlled trial, curcumin demonstrated comparable efficacy to omeprazole in treating dyspepsia and acid reflux.
-
How Many Steps a Day Will Improve Patients’ Longevity?
A systematic review and meta-analysis of studies of the association of step counts and cadence with all-cause mortality and cardiovascular events showed the benefits in these outcomes are statistically significant, at about 2,600 steps/day and peak at about 8,000 steps/day. Also, faster step cadence augments these benefits.